Ondine's Periowave(TM) Photodisinfection System Showcased at Pacific Dental
Conference in Vancouver BC
VANCOUVER, March 7 /CNW/ - Ondine Biopharma Corporation (TSX: OBP;
AIM: OBP; the "Company"), a medical technology company developing
photodisinfection based products, today announced that its Periowave(TM)
Photodisinfection System for the treatment of periodontal diseases will be
showcased at the Pacific Dental Conference (Booth No. 2020) in Vancouver BC on
March 6 - 8th, 2008.
Dr. Veronique Benhamou, DDS, a Periodontist and Director, Division of
Periodontics, and Associate Professor at McGill University, Montreal Quebec
will be speaking about Periowave(TM) and Photodisinfection today.
Dr. Benhamou's presentation is titled "Photodisinfection - The Future of
"We are very pleased to have Dr. Benhamou, a prominent Canadian
clinician, present Photodisinfection and her experience with Periowave(TM) in
the clinics at McGill University at this leading Canadian dental conference,"
stated Carolyn Cross, Ondine's President & CEO. "With over 10,000 patients
treated with Periowave(TM), clinicians across Canada and Europe are reporting
that they are seeing exceptional results when treating periodontitis,
peri-implantitis and other conditions with Periowave(TM)."
Additional information on the Pacific Dental Conference can be found at
About Periodontal Disease
Periodontitis (gum disease) is a common human affliction, affecting one
third of all adults, and over half of the population over the age of 50.
Periodontitis results in gum tissue detachment, bleeding gums, oral malodour,
bone and tooth loss as well as other complications. The standard of care for
treating periodontal disease is Scaling and Root Planing ("SRP"), or gum
surgery, or both. SRP is the sub-gingival removal of plaque biofilm adhering
to the root surfaces. Periodontitis is associated with a host of other serious
conditions including heart disease, stroke, premature births and diabetes.
About Ondine Biopharma Corporation
Ondine is developing non-antibiotic therapies for the treatment of a
broad spectrum of bacterial, fungal and viral infections. The Company is
focused on creating and commercializing leading edge products utilizing its
patented light-activated technology. Photodisinfection provides broad-spectrum
antimicrobial efficacy without encouraging the formation and spread of
antibiotic resistance. The Company is headquartered in Vancouver, British
Columbia, Canada, with a research laboratory in Bothell, Washington, USA, and
an international office in St. Michael, Barbados. For additional information,
please visit the Company's website at: www.ondinebiopharma.com.
Certain statements contained in this release containing words like
"believe", "intend", "may", "expect" and other similar expressions, are
forward-looking statements that involve a number of risks and uncertainties.
Factors that could cause actual results to differ materially from those
projected in the Company's forward-looking statements include the following:
market acceptance of our technologies and products; our ability to obtain
financing; our financial and technical resources relative to those of our
competitors; our ability to keep up with rapid technological change;
government regulation of our technologies; our ability to enforce our
intellectual property rights and protect our proprietary technologies; the
ability to obtain and develop partnership opportunities; the timing of
commercial product launches; the ability to achieve key technical milestones
in key products and other risk factors identified from time to time in the
The TSX Exchange has not reviewed and does not accept responsibility for
the adequacy or accuracy of this release.
For further information: Carolyn Cross, President and Chief Executive
Officer, Ondine Biopharma Corporation, (604) 669-0555,
ccross(at)ondinebiopharma.com; Christina Bessant, Investor Relations, The
Equicom Group Inc., (416) 815-0700 ext. 269, cbessant(at)equicomgroup.com;
Irma Gomez-Dib, Media & Investors Relations, FD International, (212) 850-5761,
Irma.gomez-dib(at)fd.com; Canaccord Adams Ltd, Nominated Adviser & Broker,
Neil Johnson, Ryan Gaffney, +4420 7050 6500